Journal of Oncology

Review Article

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

Table 2

Table showing the studies using metronomic regimens in prostate cancer.


Author	Treatment	N	Patient type	PSA	Duration of Response	PR	TTP	PFS	OS

Bracarda, 2000	CP 2 mg/kg qd days 1-14 q28 d Estramustine 10 mg/kg/day days 1-14 q28d	32	Hormone refractory	43.7%	-	-	-	-	-

Pienta, 2001	Etoposide 50mg/m2 qd days 1-21 q28d Estramustine 15 mg/kg qd days 1-21 q28d	55	Hormone refractory	22%

Nishimura, 2001	CP 100 mg qd UFT 400 mg qd Estramustine 560 mg qd	21	Hormone refractory	57%	7 m	-	-	-	-

Robles, 2003	Vinorelbine 25 mg/m2 iv q7d 12 weeks than q14d Prednisone 10 mg qd po	14	Hormone refractory, metastatic	36%

Glode, 2003	CP 50 mg qd Dexamethasone 1m g qd	34	Hormone refractory	58%	8 m	-	-	-	-

Hellerstedt, 2003	CP 100 mg days 1-20 q30d Prednisone 10 mg qd DES 1 mg qd	36	Hormone refractory	42%	4.5 m	-	-	-	16.4 m

Lord, 2007	CP 50 mg qd	58	Hormone refractory	34.5%	7.5 m	-	-	-	-

Venkirataman, 2008	Dexamethasone 0.5 mg qd	102	Castration resistant	49%

Fontana, 2009	CP 500 mg/ m² bolus than 50 mg qd po Celecoxib 200 mg bid Dexamethasone 1 mg/day po	28	Hormone refractory	32%	-	-	-	3 m	21 m

Ladoire, 2010	CP 50 mg qd Prednisolone 10 mg qd	23	Hormone refractory	26%	-	-	-	6 m	11 m

Nelius, 2010	CP 50 mg qd Dexamethasone 1 mg/day po	17	Hormone refractory	23.5%	-	-	-	-	24 m

Gebbia, 2011	CP 50 mg qd MTX 2.4 mg po two times a week LHRH analogue	58	Castration resistant,	25%	24%	28%	-	-	-

Hatano, 2011	CP 100 mg qd UFT 400 mg qd Dexamethasone 10 mg/day	57	Hormone refractory	63%	-	-	13.3 m	-	-

Jellvert, 2011	CP 50 mg bid weeks 1,3,5 Ketoconazole 200 mg tid weeks 1,3,5 Etoposide 50 mg bid weeks 2,4,6 Estramustine 140 mg bid weeks 2,4,6	17	Castration resistant,	59%	-	-	-	-	-

Khan, 2011	CP 50 mg qd MTX 2.5 mg bid two times a week Celecoxib 400 mg bid	69	Hormone refractory	N/A			57 days

Meng, 2012 ®	CP 50 mg qd Capecitabine 1000 mg bid Thalidomide 100 mg qd Prednisone 5 mg bid	28	Castration resistant,	35.7%	-	-	-	4.7 m	19.5 m

Orlandi, 2013	CP 50 mg qd Cetuximab 200 mg bid po Dexamethasone 1 mg qd po	43	Castration resistant,	32%	-	-	-	634CC 2.2 m 634CG/GG 6.25 m	-

Derosa, 2014	CP 50 mg qd po Docetaxel 06 mg/ m² in q21d Prednisone 10 mg qd from day 2 Celecoxib 400 mg qd	41	Castration resistant, untreated	82%	-	-	-	-	-

Yashi, 2014	CP 50 mg qd po Dexamethasone 1 mg qd po	24	Castration resistant, metastatic	33.3%	-	-	-	5.0 m	19.0 m

Zhu, 2014	Etoposide 25mg/m2 bid days 1-21, q28d Prednisone 5 mg bid days 1-21, q28d	39	Castration resistant,	41%				5.9 m

Barroso-Sousa, 2015 ®	CP 50 mg qd or CP 150 mg days 1-14, q21d Prednisone 10 mg po	40	Castration resistant, pretreated, metastatic	20%	-	-	-	-	-

Wang, 2015	CP 50 mg qd po Lenalidomide 25 mg qd days 1-21 q28d	6	Castration resistant, metastatic	31.7%	-	-	-	-	-

Petrioli, 2015	Abiraterone 25 mg qd po Prednisone 5 mg qd po	26	Castration resistant	69.2%				6.4 m	14.3 m